#398 What’s 340B? An Economist’s View of the Recent Wave of 340B Litigation
The Federal 340B Drug Pricing Program has grown from a modest drug discount program into […]
#397 What’s Next for the ABA Antitrust Law Section? Stability, Balance, and Value
What’s ahead for the ABA Antitrust Law Section in 2026–2027? Section Chair Melanie Aitken and […]
#394 A Tribute to Randy Picker: Revisiting Episode #74 on the Implications of DOJ’s Case Against IBM
We are re-releasing this episode in tribute to Prof. Randy Picker, who passed away on […]
#393 Who Gets To Say the Price Is Right? State Regulation of AI Pricing
Several U.S. states have recently passed legislation aimed at AI pricing tools that use consumer […]
#389 What Should Directors Be Asking? Antitrust in the Boardroom
Competition law isn’t just for antitrust lawyers anymore—it’s increasingly a boardroom issue. What questions should […]
#387 Can Potential Vertical Integration Harm Be (Silver) Screened Horizontally?
Vertical merger review has long rested on the principle that competitive harm is most likely […]
#385 How Do We Level the AI Fluency Playing Field? The 21 Days of AI Grit and Growth Mindset Challenge
Are you as AI fluent as you should be? The American Bar Association’s “21 Days […]
#383 What’s the Role of Communications Strategy in M&A? How Public Affairs Impacts Antitrust
Recently, the role of lobbying in M&A has become the talk of the antitrust bar […]
#372 Can a Price Be Put on Harm? FTC Monetary Remedies and the Data-Driven Economy
Five years after the Supreme Court’s AMG Capital Management decision limited the FTC’s ability to […]
#369 Back To Form or Back to the Drawing Board? How To Navigate the Decision Vacating the New HSR Rules
In February 2025, new rules for the pre-merger notification requirements in the U.S. came into […]